iRhythm Holdings, Inc. IRTC

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

iRhythm is a leading digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Our principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that we believe allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology.

Each iRhythm product offering combines a wire-free, patch-based, 14-day wearable biosensor (United States Food and Drug Administration ("FDA")-cleared, Conformité Européenne ("CE")-marked and Japan Pharmaceuticals and Medical Devices Agency ("PMDA")-approved, as applicable) that continuously records electrocardiogram ("ECG") data with a proprietary cloud-based data analytic software (also FDA-cleared, CE-marked and Japan PMDA-approved, as applicable) (such biosensor and software together, an "iRhythm ACM System") to help physicians monitor patients and diagnose arrhythmias.

Last close 121.27 2026-10-23
Market cap $4.00B 2026-06-30 share count
52-week range 100.70 - 212.00

Valuation FY2025 figures against the last close

P/S5.4x
P/E—
P/FCF115.8x
EV/EBITDA—
Dividend yield—
Diluted EPS-1.39

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $747.1M$591.8M$492.7M$410.9M$322.8M$265.2M$214.6M$147.3M$99.1M$64.1M
Cost of revenue $219.9M$184.3M$160.9M$129.3M$109.3M$70.3M$52.5M$38.8M$28.2M$20.9M
Gross profit $527.2M$407.5M$331.8M$281.6M$213.6M$194.9M$162.1M$108.5M$70.9M$43.2M
R&D ——$60.2M$46.6M$38.7M$41.3M$37.3M$20.9M$13.3M$7.2M
SG&A $492.6M$418.6M$385.6M$322.2M$274.8M$197.2M$179.5M$133.3M$85.3M$51.6M
Total operating expenses $584.7M$523.0M$457.0M$395.4M$313.5M$238.6M$216.8M$154.2M$98.5M$58.8M
Operating income -$57.4M-$115.5M-$125.2M-$113.8M-$99.9M-$43.7M-$54.8M-$45.7M-$27.6M-$15.6M
Interest expense $13.2M$12.8M$3.6M$4.1M$1.2M$1.5M$1.6M$3.1M$3.4M$3.2M
Pre-tax income -$43.6M-$112.7M-$122.7M-$115.9M-$101.0M-$43.6M-$54.5M-$50.3M-$29.7M-$20.9M
Income tax $953.0K$565.0K$750.0K$269.0K$367.0K$229.0K$65.0K$44.0K$0$0
Net income -$45.0M-$113.0M-$123.0M-$116.0M-$101.0M-$43.8M-$54.6M-$50.4M-$29.7M-$20.9M
EPS, basic -1.39-3.63-4.04-3.88-3.46-1.58-2.16———
EPS, diluted -1.39-3.63-4.04-3.88-3.46-1.58-2.16-2.11-1.31-3.95
Shares, diluted (wtd. avg.) 32.0M31.2M30.5M29.9M29.3M27.8M25.3M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $236.0M$419.6M$36.2M$78.8M$127.6M$88.6M$20.5M$20.0M$8.7M$51.6M
Short-term investments $347.8M$116.0M$97.6M$134.3M$111.6M$246.6M$120.1M$58.3M$93.7M$54.4M
Receivables $75.7M$79.9M$61.5M$49.9M$46.4M$29.9M$23.9M$19.8M$13.0M$9.4M
Inventory $21.6M$14.0M$14.0M$15.2M$10.3M$5.3M$4.0M$2.1M$1.7M$1.4M
Total current assets $702.8M$645.8M$230.8M$288.8M$305.5M$377.8M$172.8M$104.3M$119.6M$118.6M
Property, plant and equipment $151.6M$125.1M$104.1M$75.7M$55.9M$34.2M$26.5M$9.2M$6.2M$4.7M
Goodwill $862.0K$862.0K$862.0K$862.0K$862.0K$862.0K$862.0K$862.0K$862.0K$862.0K
Total assets $1.02B$931.4M$433.1M$448.2M$463.0M$511.7M$306.2M$117.5M$133.1M$138.2M
Accounts payable $2.3M$7.2M$5.5M$7.5M$10.5M$4.4M$8.2M$2.3M$2.4M$2.1M
Short-term debt ———$0$11.7M$11.7M$1.9M$0$1.5M—
Total current liabilities $151.9M$110.9M$107.4M$89.1M$87.9M$65.7M$52.1M$30.3M$20.9M$13.2M
Long-term debt ——$35.0M$34.9M$9.7M$21.3M$33.0M$34.9M$32.5M$32.2M
Total liabilities $867.3M$840.5M$223.0M$208.4M$183.5M$170.1M$170.8M$65.4M$53.6M$45.6M
Retained earnings -$803.4M-$758.9M-$645.6M-$522.2M-$406.0M-$304.7M-$260.4M-$205.8M-$156.6M-$127.2M
Total equity $152.7M$90.9M$210.1M$239.8M$279.5M$341.6M$135.4M$52.1M$79.3M$93.0M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $80.9M$3.4M-$50.1M-$23.0M-$37.8M-$13.8M-$21.9M-$29.1M-$14.9M-$16.7M
Depreciation and amortisation $20.7M$20.7M$16.3M$13.4M$9.8M$6.9M————
Stock-based compensation $88.3M$76.0M$77.2M$57.7M$54.5M$41.5M$26.2M$16.3M$9.8M$1.9M
Capital expenditure $46.3M$33.9M$40.4M$29.8M$28.1M$13.6M$20.5M$5.2M$3.6M$2.8M
Investing cash flow -$277.1M-$123.0M-$1.2M-$52.4M$105.3M-$132.4M-$89.3M$34.1M-$34.7M-$68.2M
Financing cash flow $12.6M$511.4M$8.8M$26.7M-$28.6M$214.3M$111.6M$6.3M$6.5M$111.3M
Buybacks $0$25.0M$0$0——————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001388658-26-000030.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -250M 0 250M 500M 750M Revenue, FY2016: 64.1M Gross profit, FY2016: 43.2M Net income, FY2016: -20.9M Revenue, FY2017: 99.1M Gross profit, FY2017: 70.9M Net income, FY2017: -29.7M Revenue, FY2018: 147.3M Gross profit, FY2018: 108.5M Net income, FY2018: -50.4M Revenue, FY2019: 214.6M Gross profit, FY2019: 162.1M Net income, FY2019: -54.6M Revenue, FY2020: 265.2M Gross profit, FY2020: 194.9M Net income, FY2020: -43.8M Revenue, FY2021: 322.8M Gross profit, FY2021: 213.6M Net income, FY2021: -101M Revenue, FY2022: 410.9M Gross profit, FY2022: 281.6M Net income, FY2022: -116M Revenue, FY2023: 492.7M Gross profit, FY2023: 331.8M Net income, FY2023: -123M Revenue, FY2024: 591.8M Gross profit, FY2024: 407.5M Net income, FY2024: -113M Revenue, FY2025: 747.1M Gross profit, FY2025: 527.2M Net income, FY2025: -45M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $64.1M $99.1M $147.3M $214.6M $265.2M $322.8M $410.9M $492.7M $591.8M $747.1M
Gross profit $43.2M $70.9M $108.5M $162.1M $194.9M $213.6M $281.6M $331.8M $407.5M $527.2M
Net income -$20.9M -$29.7M -$50.4M -$54.6M -$43.8M -$101.0M -$116.0M -$123.0M -$113.0M -$45.0M

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Material agreement signed Item 1.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Cybersecurity incident A cybersecurity incident the company has determined to be material. Required since December 2023. Item 1.05
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%